In this video, I break down whether Eli Lilly stock is still a strong buy in 2026 after an explosive year of growth. I will walk you through the company’s latest earnings report, revenue guidance, blockbuster obesity drugs like Mounjaro and Zepbound, and its powerful pipeline including orforglipron

AI-generated source summary

Eli Lilly and Company (LLY) is showing strong financial performance with significant revenue growth driven by its key products, Mounjaro and Zepbound. The company's robust pipeline, including promising phase 3 trial results for tirzepatide in obesity and various other drug candidates, along with strategic acquisitions, positions it for continued expansion. Analysts maintain a strong buy rating, indicating confidence in future earnings growth and capital gains, supported by a consistent and well-covered dividend. The stock's low beta suggests it's a defensive compounder, offering a combination of growth and stability.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   18 Feb 2026, 01:00 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:24 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:12 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:12 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:12 UTC

   All evaluable predictions in this case reached terminal outcomes.